Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
City of Hope Medical Center
City of Hope Medical Center
Nurix Therapeutics, Inc.
Verismo Therapeutics
Nurix Therapeutics, Inc.
Massachusetts General Hospital
Medical College of Wisconsin
Newave Pharmaceutical Inc
Schrödinger, Inc.
Mayo Clinic
LTZ Therapeutics, Inc.
AbbVie
UNC Lineberger Comprehensive Cancer Center
University of California, San Francisco
Carna Biosciences, Inc.
Mayo Clinic
Accutar Biotechnology Inc
Acepodia Biotech, Inc.
Stanford University